ClinicalTrials.gg
CompletedNCT01730014Updated Jul 31, 2013

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

A Phase 1 interventional study of 148-0287-A-4.2mM-cartridge and placebo in Diabetes, Diabetes Mellitus, Type 1 and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-31.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
34th of 66
70 · median 73
Started
2012
with 7 others
Phase 1
14 of 66
none open now
Registered
42nd of 66
by date
Lead sponsor
11 of 66
Novo Nordisk A/S

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 34th largest by enrollment, is one of 8 that started in 2012, is one of 14 in phase 1, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneous NNC0148-0000-0287 (insulin 287) in healthy subjects and in subjects with type 1 diabetes

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Healthy

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 70 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • TRIAL PART 1 (HEALTHY SUBJECTS):
  • Healthy male subject
  • Age 18-55 years (both inclusive)
  • 18.0-28.0 kg/m\^2 (both inclusive)
  • TRIAL PART 2 (SUBJECTS WITH TYPE 1 DIABETES):
  • Healthy male subject (with the exception of conditions associated with diabetes mellitus)
  • Age 18-64 years (both inclusive)
  • Body mass index 18.0-28.0 kg/m\^2 (both incl.)
  • Type 1 diabetes mellitus (as diagnosed clinically) and treated with multiple daily insulin injections more than 12 months
  • (glycosylated ) below or equal to 8.5 %
  • Current daily basal insulin requirement above or equal to 0.2 to below or equal to 0.8 (I)U/kg/day and current total daily insulin treatment below 1.2 (I)U/kg/day
  • Fasting C-peptide below 0.3 nmol/L

Exclusion criteria

Exclusion Criteria:

  • The receipt of any medicinal product within the last 3 months prior to the start of this trial (screening)
  • Significant blood loss (due to donation, surgery or trauma) of more than 500 mL within 3 months prior to the start of this trial (screening) or participating in any other trial involving blood sampling within the last 2 months before the start of this trial (screening)
  • Use of any prescription (see specification below for Trial Part 2) or non-prescription medication, including herbal products and non-routine vitamins, within the last 2 weeks before the start of the trial (screening) that will interfere with the pharmacokinetics of insulin 287, as judged by the investigator in agreement with the sponsor. Routine vitamins and occasional use judged by the investigator in agreement with the sponsor. Routine vitamins and occasional use of paracetamol is permitted up to 48 hours prior to dosing
  • History of alcoholism or drug abuse (within the last 2 years), or positive result of alcohol or drug screening test
  • Currently smoke more than 1 cigarette per day (or the equivalent for other tobacco products) or smoking 1 cigarette or less per day and not considering being able to refrain from smoking or refrain from use of other types of nicotine products (e.g. such as chewing tobacco, nicotine gums) during the in-house periods
  • Habitual excessive consumption of methylxanthine-containing (theophylline, caffeine or theobromine) beverages and foods (coffee, tea, soft drinks such as red bull, cola, chocolate) as judged by the investigator
  • Excessive consumption of a diet deviating from a normal diet as judged by the investigator
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation in the trial
  • Vulnerable subjects (e.g. persons kept in detention)
  • Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial
  • ADDITIONAL KEY EXCLUSION CRITERIA TRIAL PART 2 (subjects with type 1 diabetes):
  • Current treatment with statins, systemic (oral, intravenous or inhaled) , monoamine oxidase (MAO) inhibitors, non-selective beta-blockers, thyroid hormones, growth hormone and other drugs, which may interfere with glucose metabolism
  • Increased risk of thrombosis, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the investigator
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the past 6 months before start of this trial (screening)
  • Cardiac problems defined as: decompensated heart failure ( (NYHA) class III and IV) at any time, or acute myocardial infarction at any time, or angina pectoris within the last 12 months before start of this trial (screening)
  • Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy, as judged by the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Trial part 1

    Drug: 148-0287-A-4.2mM-cartridge · Drug: placebo

  • Experimental
    Trial part 2, treatment A

    Drug: 148-0287-A-4.2mM-cartridge · Drug: sodium chloride 0.9% w/v

  • Experimental
    Trial part 2, treatment B

    Drug: placebo · Drug: insulin glargine

Interventions

  • Drug148-0287-A-4.2mM-cartridge

    In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.

  • Drugplacebo

    In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.

  • Drug148-0287-A-4.2mM-cartridge

    In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

  • Drugplacebo

    In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

  • In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

  • Drugsodium chloride 0.9% w/v

    Drug page: Sodium Chloride

    In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AE)

    Time frame: From trial product administration until completion of the post-treatment follow-up visit at Day 37

Secondary outcomes

  1. Incidence of hypoglycaemic episodes

    Time frame: From trial product administration until completion of the post-treatment follow-up visit at Day 37

  2. AUC, the area under the serum insulin 287 concentration-time curve

    Time frame: From dosing visit to infinity calculated from a 0-36 days NNC0148-0287 serum concentration-time-curve based on 43 sampling time points

  3. Cmax, the maximum serum insulin 287 concentration

    Time frame: Observed (within 0-36 days)

  4. tmax, the time for maximum serum insulin 287 concentration

    Time frame: Within 0-36 days

  5. Average morning fasting blood glucose (FBG) concentration

    Time frame: From Day 2 to Day 8

  6. Average morning fasting serum C-peptide concentration

    Time frame: From Day 2 to Day 8

  7. Average morning fasting serum free fatty acid (FFA) concentration

    Time frame: From Day 2 to Day 8

  8. Area under the glucose infusion rate (GIR)-time curve

    Time frame: At Day 1-2, 4-5, or 7-8

  9. The maximal GIR (glucose infusion rate) observed

    Time frame: At Day 1-2, 4-5, or 7-8

08

Study locations

1 site
  • Neuss, 41460, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2012
First posted
Nov 21, 2012
Start
Oct 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Jul 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01730014
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Oct 2012
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Jul 31, 2013

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Sodium Chloride

Start the discussion